 Marker Therapeutics Inc NASDAQ: MRKR received notice of a Product Development Research award of approximately 13.1 million from Texass Cancer Prevention and Research Institute CPRIT. The CPRIT award is intended to support the adjuvant arm Phase 2 trial of its MultiTAA-specific T cell product MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia AML following a hematopoietic stem cell transplant. 